ChloraSolv is available in the UK through NHS Supply Chain
As of 11th of July 2022, ChloraSolv is available in the UK to NHS (National Health Service) organizations who purchase from NHS Supply Chain or directly from ConvaTec. ChloraSolv is available to all NHS facilities who have an account at NHS Supply Chain. It is applicable to a range of settings, including hospitals as well as primary and home care settings. ChloraSolv also can be purchased directly from ConvaTec, RLS' exclusive distribution partner for ChloraSolv in Europe.
ChloraSolv’s inclusion on the NHS Supply Chain advanced wound care framework is the first step to enabling access to the UK market. In parallel, RLS and ConvaTec are working together to provide broader access to ChloraSolv across the UK, through additional routes to market.
Karin Fischer, CEO, RLS Global, says: “The UK is a strategic important market for advanced wound care and we are delighted to build on our strategic partnership with ConvaTec to bring this solution to the NHS.”
RLS, together with ConvaTec, have worked to evaluate the technology and collect relevant data to secure approved access to the NHS Supply Chain. Wound debridement supports faster healing of wounds and is a fundamental part of wound management. It reduces the negative impact from hard to heal wounds on patients’ quality of life. It also reduces the healthcare resources needed to support patients.
ChloraSolv is a new innovative option for wound cleansing and debridement/desloughing and reducing microbiological load. It is a unique gel application, intended for use in adult patients with chronic leg ulcers and diabetic foot ulcers in need of debridement.
ChloraSolv provides a convenient, effective and gentle option for debridement.
THIS IS CHLORASOLV:
ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.1 ChloraSolv does not damage healthy tissue and is well tolerated by the patient.
- Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. An open single arm multicenter pilot investigation to evaluate the debriding effect of amino acid buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during six weeks treatment. Journal of Wound Care (Accepted for publication).
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012–2017, the company was listed on Aktietorget.
FOR MORE INFORMATION, PLEASE CONTACT:
Karin Fischer, CEO, RLS Global
E-mail: karin.fischer@rlsglobal.se
Tel: +46 702 48 46 51
ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products for some of our most common diseases in wound and dental care. RLS has a portfolio of strong brands, including ChloraSolv® and Carisolv®.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS intends to work with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global
Tags: